Native Cardio Board of Directors

Dr. Joseph V. Pergolizzi., MD

Joseph Pergolizzi, MD, Executive Chairman – Dr. Joseph V. Pergolizzi, Jr. is an internationally recognized thought leader in anesthesiology, internal medicine, perioperative care, pain medicine, critical and palliative care, pharmacology, drug development and regulatory affairs. As a drug and device regulatory subject matter expert, Dr. Pergolizzi is a top consultant for numerous blockbuster-branded medications.  He is an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Native Cardio.

He is the co-founder of NEMA Research, Inc., a specialty CRO, a former invited subcommittee member of the FDA Safe Use Initiative, an SGE VAH Grant Reviewer, a section Chairman of PAINWEEK, and Consultant to Global Pain Initiative’s Board of Directors. Dr. Pergolizzi is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit and a former part-time adjunct faculty member in the Department of Medicine at Johns Hopkins University School of Medicine.

Dr. Pergolizzi has published over 100 peer-reviewed medical articles and is frequently invited to share his presentations at scientific conferences around the world.

Young D. Kim, MD, Board Member and Co-founder – Dr. Kim is former Chairman and Professor, Department of Anesthesia, Georgetown University Medical Center 2004-2012. Dr. Kim is a former NIH researcher with over 40-years of cardiovascular anesthesia clinical and research experience. Dr. Kim has been awarded multiple research grants for his work and has exhibited his findings at numerous scientific conferences. Dr. Kim is the author of over 150 peer-reviewed articles, abstracts, and platform presentations in his areas of interest and expertise. He is an internationally recognized expert and is in demand as a lecturer. He holds U.S. patents for his innovations.

Pedro Granadillo, Board Member – Pedro is a highly-respected pharmaceutical business leader with over 40 years of experience in the industry and a proven track record in human resources, manufacturing, quality and corporate governance. He has expertise in multiple areas, including designing and operating complex global manufacturing networks, senior leadership development and succession planning, executive and non-executive compensation, organizational transformation, and portfolio management. He possesses over 2 decades of international experience, with direct global responsibility for Manufacturing, Quality and Human Resources and 13 years in leadership roles in Europe. He served as Senior Vice President for Eli Lilly and Company until his retirement in 2004 after 34 years of service. As a member of Lilly’s Executive Committee and as Lilly’s head of human resources, manufacturing and quality, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as a broad network of manufacturing facilities for its extensive line of products. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly’s conventional “small-molecule” pharmaceuticals and “large-molecule” biotech therapies.

Pedro has received a number of awards over the course of his career, including the Purdue University Distinguished Alumni Award. While at Lilly, he led their efforts in affirmative action, diversity, and progressive employment, resulting in Lilly’s receipt of the Opportunity 2000 Award from the US Dept. of Labor, and Lilly’s naming to the “Best Companies to Work For” by Working Mother Magazine for every year during his tenure.

Since his retirement from Lilly, Pedro has been involved in a number of public and private companies in the biotechnology and medical device fields. He currently serves on the Board of Directors of Haemonetics Corporation, Braintree, MA, Rocket Pharmaceuticals, New York City, New York and Neumentum Corporation, a privately held company that he co-founded. He previously served on the Boards of Directors of Dendreon Corporation, Noven Pharmaceuticals, First Indiana Bank and most recently on the Board of Directors of NPS Pharmaceuticals, which sold to Shire for $5.2 Billion in 2015.

Pedro earned his B.S. degree in Industrial Engineering from Purdue University.

Mark Kroll, Ph.D., FACC, FHRS, Board Member – Dr. Kroll holds a B.S. in mathematics, a Ph.D. in electrical engineering, and an M.B.A. Dr. Kroll retired as Chief Technology Officer and Senior Vice President of the Cardiac Rhythm Management Division of St. Jude Medical, Inc. Dr. Kroll has significant experience in business and technology development and acquisition integration. He is an experienced public and private company board member. Dr. Kroll currently serves on the Board of Directors for Haemonetics Corporation and Axon Enterprises, Inc. He has been honored with the Fellow designation from both The American College of Cardiology and the Heart Rhythm Society.

Christine Mikail, Board Member – Christine Mikail has almost 20 years of experience managing and advising a number of public and private biotech and pharmaceutical companies. Ms. Mikail is a Co-Founder, Director and Chief Business Officer of Neumentum, a non-opioid analgesic and neurology specialty pharmaceutical company.  She is responsible for business development, finance, and operations and led the financing strategy for the Series A and A-1 Financings.

Ms. Mikail is also the founder of DCA Advisory where she is currently advising several start-up and private biotech companies around operations, business development, and financings.  She is also an Adjunct Professor at the Rutgers Business School in New Jersey. From March 2015 to March 2017, she was Chief Administrative Officer, Head of External Business Development and Alliance Management, and General Counsel at Axovant Sciences, Inc., where she helped raise $362 million in one of the largest biotech Initial Public Offerings. Most recently, Ms. Mikail served on the Board of Advanced Accelerator Applications through its acquisition by Novartis for $3.9B. Prior to this, Ms. Mikail served as Senior Vice President of Legal Affairs, General Counsel and Secretary at NPS Pharmaceuticals, Inc., where she was an integral part of the deal team that sold NPS Pharma to Shire Pharmaceuticals for $5.2 billion.

Ms. Mikail’s other positions include senior leadership roles in corporate/business development and legal at Dendreon Corporation, Savient Pharmaceuticals, ImClone Systems Corporation and later Eli Lilly, following its acquisition of ImClone.

Prior to joining the pharmaceutical industry, Ms. Mikail practiced corporate law at Reed Smith, LLP, Lowenstein Sandler PC, and Wilmer Hale. Ms. Mikail holds a Juris Doctorate from Fordham Law School and a Bachelor of Arts degree Cum Laude from Rutgers University.